Nipocalimab is a fully human, anti-FcRn, aglycosylated IgG1 monoclonal antibody that reduces pathogenic alloantibodies in maternal circulation and blocks the placental transfer of maternal IgG to the ...
Please provide your email address to receive an email when new articles are posted on . Alloimmunization rates were 6.2% for women matched to ABO and Rhesus D and 1.9% for women also matched for c, E ...
Please provide your email address to receive an email when new articles are posted on . Practice patterns vary widely for management of hemolytic disease of the fetus and newborn (HDFN). Researchers ...
Breakthrough Therapy Designation for nipocalimab based on results from the Phase 2 UNITY clinical trial for HDFN Phase 3 clinical trial enrollment underway, representing the only therapy reported to ...
Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Intravenous nipocalimab was administered from 14 to 35 weeks of gestation in participants with pregnancies at high risk for recurrent early-onset severe HDFN. HealthDay News — For pregnancies at high ...
Researchers are leading a study into nipocalimab, a new investigational drug that's showing promise in treating a rare blood disease in babies. It could help prevent anemia and cut down on the need ...
Data from the pivotal ENERGY trial showed IMAAVY® produced a rapid and durable hemoglobin responsea in wAIHA Currently no FDA-approved therapies are available for wAIHA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results